Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Pazopanib

An oral multi-tyrosine kinase inhibitor (VEGFR, PDGFR, c-KIT) that curbs the growth of the blood vessels feeding a tumour: approved in the United States in 2009 for advanced renal cell carcinoma and in 2012 for some soft tissue sarcomas. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.

Did you know?Because it also blocks the c-KIT receptor, on which pigment-making melanocytes depend, it lightens the hair of about a third of patients: an effect that usually fades after treatment stops.

PazopanibGo to the active ingredient →
PazopanibActive ingredientPazopanibCat. No. P-P030-001CAS 444731-52-6
Pazopanib-d6Isotopically labelledPazopanib-d6Cat. No. P-P030-004CAS 1219592-01-4

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.